Question: {'question': 'Imagine a situation where a novel natural molecule, Xantheraquin, is discovered and is being investigated for in silico testing against a bacterial pathogen that is multidrug resistant. Preliminary studies indicate that Xantheraquin has multiple chiral centers and can exist in various tautomeric forms. Which of the following steps would be the MOST crucial before proceeding with in silico docking studies, given the complexities of bioinformatics in structure-based drug discovery, ?', 'choice1': 'Use the most stable chiral form of Xantheraquin, relying on quantum mechanical calculations to predict its interaction with the bacterial target.', 'choice2': 'Combine in silico predictions with preliminary in vitro binding affinity assays to validate the most promising forms of Xantheraquin before extensive docking studies.', 'choice3': 'Analyze all tautomeric and chiral forms, but prioritize those forms that are most likely to be biologically active based on physicochemical properties.', 'choice4': "Focus on Xantheraquin's pharmacokinetics and ADME (Absorption, Distribution, Metabolism, Excretion) properties, using molecular dynamics simulations to predict its behavior in a biological system."}
Iteration: abstracted_workflow_2
Full Response:[Info(name='thinking', author='Chain-of-Thought Agent aQfl', content='Without specific structural representations (e.g., SMILES or 3D coordinates) for each tautomeric and stereoisomeric form of Xantheraquin, we cannot compute exact pKa, logD, or conformational energies. We can only propose a generic prioritization framework based on typical physicochemical trends and likely bioactive species.\n\nAnswer:1. Neutral keto tautomers predominant at pH 7.4 (logD ~1–3), low conformational strain, favorable PSA—highest priority for initial docking.\n2. Singly protonated enol or zwitterionic forms with moderate lipophilicity (logD ~0–2) and pKa near physiological pH—second priority.\n3. Minor high-energy tautomers or doubly charged species with poor membrane permeability and high strain—deprioritize.\n4. Within each tautomeric group, prioritize stereoisomers with the lowest calculated DFT/force-field energies and R/S configurations predicted to complement the chiral binding pocket.\n[TOO_HARD]\nPlease provide the SMILES or high-resolution 3D structures for each chiral and tautomeric form of Xantheraquin to calculate precise energetics, pKa, and logD values and finalize the ranking.', prompt=[{'role': 'system', 'content': "You are a helpful assistant.\n\nReply EXACTLY with the following JSON format.\n{'thinking': 'Your thinking.', 'answer': 'Your answer. If the question is asked for a multiple-choice result, Return ONLY the alphabet choice, i.e. A) or B) or C) or D); If the question is asked for more than multiple-choice results, Return what the question asked and make sure the answer is complete.'}\nDO NOT MISS ANY REQUEST FIELDS and ensure that your response is a well-formed JSON object!\n\n"}, {'role': 'user', 'content': 'Related original question:\n\n{\'question\': \'Imagine a situation where a novel natural molecule, Xantheraquin, is discovered and is being investigated for in silico testing against a bacterial pathogen that is multidrug resistant. Preliminary studies indicate that Xantheraquin has multiple chiral centers and can exist in various tautomeric forms. Which of the following steps would be the MOST crucial before proceeding with in silico docking studies, given the complexities of bioinformatics in structure-based drug discovery, ?\', \'choice1\': \'Use the most stable chiral form of Xantheraquin, relying on quantum mechanical calculations to predict its interaction with the bacterial target.\', \'choice2\': \'Combine in silico predictions with preliminary in vitro binding affinity assays to validate the most promising forms of Xantheraquin before extensive docking studies.\', \'choice3\': \'Analyze all tautomeric and chiral forms, but prioritize those forms that are most likely to be biologically active based on physicochemical properties.\', \'choice4\': "Focus on Xantheraquin\'s pharmacokinetics and ADME (Absorption, Distribution, Metabolism, Excretion) properties, using molecular dynamics simulations to predict its behavior in a biological system."}. \n\nRelated sub-task questions and answers:\n\n### Sub-task 1: Analyze the molecular structure of Xantheraquin to identify and classify all chiral centers and tautomeric forms, considering the complexity introduced by multiple chiral centers and tautomerism. \n\n ### thinking by Chain-of-Thought Agent w6rY:\nThe user requests classification of all chiral centers and tautomeric forms, but no actual chemical structure data (e.g. SMILES, 2D drawing) is provided. Without the molecular details, it is impossible to enumerate specific stereocenters or tautomers. I\'ll outline a general workflow and request the missing structural information.\n\n### answer by Chain-of-Thought Agent w6rY:\nGeneral workflow to identify and classify chiral centers and tautomers for Xantheraquin:\n1. Obtain a precise 2D/3D representation of Xantheraquin (e.g., SMILES, InChI or a drawn structure).\n2. Use cheminformatics software (e.g., RDKit, OpenBabel) to parse the structure.\n3. Apply CIP (Cahn–Ingold–Prelog) rules to each sp3 carbon to identify and assign R/S configuration.\n4. Enumerate all possible stereoisomers resulting from the multiple chiral centers.\n5. Identify labile hydrogen positions (e.g., on heteroatoms like N, O) and conjugated systems that can tautomerize.\n6. Generate all tautomeric forms computationally (e.g., using ChemAxon’s tautomer enumeration).\n7. Filter tautomer set by chemical stability and likely physiological pH state.\n8. Catalog each unique stereoisomer–tautomer combination for downstream analysis.\n\n[TOO_HARD]\nPlease provide the detailed molecular structure (SMILES or high-resolution 2D/3D diagram) of Xantheraquin so we can enumerate and classify its specific chiral centers and tautomeric forms.\n\n### Sub-task 2: Based on the identified chiral and tautomeric forms from Sub-task 1, evaluate the physicochemical properties of each form to understand their stability and potential biological relevance. \n\n ### thinking by Chain-of-Thought Agent 0XNI:\nSub-task 2 requires concrete structural representations (e.g., SMILES or 3D coordinates) for each stereoisomeric and tautomeric form of Xantheraquin to compute accurate physicochemical descriptors. Without those details, we can only outline a general protocol. The question is too open-ended for precise values, so I will provide the evaluation workflow and then request the missing structural data.\n\n### answer by Chain-of-Thought Agent 0XNI:\nGeneral workflow to evaluate physicochemical properties of each chiral/tautomeric form:\n1. Protonation/tautomeric state analysis: predict dominant species at physiological pH (pKa calculations using quantum methods or tools like Marvin).\n2. Lipophilicity and solubility: compute logP/logD (e.g., with ALOGPS or ChemAxon), aqueous solubility predictions.\n3. Conformational energy: perform geometry optimizations (DFT or force field) to estimate relative stability of each stereoisomer and tautomer.\n4. Dipole moment and polar surface area: calculate via quantum chemical methods to infer membrane permeability and hydrogen-bonding potential.\n5. Strain and torsional energies: analyze low-energy conformers to assess the likelihood of bioactive conformations.\n6. Druglikeness filters: check Lipinski’s rule of five, Veber criteria, and other ADME-related descriptors for each form.\n7. Rank the forms by a composite score balancing stability and predicted bioavailability; prioritize forms that are neutral or singly charged, moderately lipophilic (logD ~1–3), and low in strain.\n\n[TOO_HARD]\nPlease provide the SMILES or high-resolution 3D structures for all proposed chiral and tautomeric forms of Xantheraquin so we can compute specific physicochemical parameters and complete the evaluation.\n\n### Sub-task 3: Prioritize the chiral and tautomeric forms of Xantheraquin based on their physicochemical properties and likelihood of biological activity, integrating knowledge from the structural analysis and property evaluation. \n\n ### thinking #1 by Chain-of-Thought Agent aQfl (yourself):\nSub-task 3 requires ranking specific stereoisomeric and tautomeric forms by their precise physicochemical parameters (e.g., logD, pKa, conformational energies). Without concrete structural representations (e.g., SMILES or 3D coordinates), we can only outline a general prioritization framework but cannot assign actual identities or values. Therefore, additional structural information is needed to finalize the list.\n\n### answer #1 by Chain-of-Thought Agent aQfl (yourself):\nGeneral prioritization framework for Xantheraquin’s isomeric forms:\n1. Neutral keto tautomers predominant at pH 7.4 with logD between 1–3, low conformational strain, and favorable polar surface area.\n2. Singly protonated (enol or zwitterionic) forms with moderate lipophilicity (logD ~0–2) and pKa values near physiological pH enhancing binding potential.\n3. Minor high-energy tautomers or doubly charged species with poor membrane permeability and high strain—deprioritize for initial docking.\n4. Among stereoisomers, prioritize those with lowest calculated DFT/force-field energies and R/S configurations predicted to match the chiral environment of the target’s binding pocket.\n\n[TOO_HARD]\nPlease provide the SMILES or high‐resolution 2D/3D structures for each proposed chiral and tautomeric form of Xantheraquin so we can compute accurate energetics, pKa, and logD values to refine this prioritization.\n\n### Please review the prioritization of chiral and tautomeric forms and provide limitations. \n\n ### feedback #1 by Critic Agent RqcZ:\nThe proposed prioritization framework is conceptually sound but hampered by a lack of concrete structural data. Without SMILES or 3D coordinates for each tautomeric and stereoisomeric form, the values for logD, pKa, and conformational energies remain speculative. Additionally, the framework omits considerations of tautomer interconversion kinetics, actual population distributions under physiological conditions, and explicit stereochemical matching to the binding site’s chiral environment. As a result, the prioritization cannot be definitively applied or validated.\n\nGiven the above, answer the following question: Sub-task 3: Prioritize the chiral and tautomeric forms of Xantheraquin based on their physicochemical properties and likelihood of biological activity, integrating knowledge from the structural analysis and property evaluation.\n\nIf the question is too complicated or informaion is missing, you still need to give your best answer but add (1) an additional mark [TOO_HARD] in the next line of your final answer (2) information request or decomposison suggestion in the next line of the [TOO_HARD] mark, in the "answer" entry and justify why you think so in the "thinking" entry'}], sub_tasks=None, agents="CoT agent w6rY, analyzing molecular structure, thinking: The user requests classification of all chiral centers and tautomeric forms, but no actual chemical structure data (e.g. SMILES, 2D drawing) is provided. Without the molecular details, it is impossible to enumerate specific stereocenters or tautomers. I'll outline a general workflow and request the missing structural information.; answer: General workflow to identify and classify chiral centers and tautomers for Xantheraquin:\n1. Obtain a precise 2D/3D representation of Xantheraquin (e.g., SMILES, InChI or a drawn structure).\n2. Use cheminformatics software (e.g., RDKit, OpenBabel) to parse the structure.\n3. Apply CIP (Cahn–Ingold–Prelog) rules to each sp3 carbon to identify and assign R/S configuration.\n4. Enumerate all possible stereoisomers resulting from the multiple chiral centers.\n5. Identify labile hydrogen positions (e.g., on heteroatoms like N, O) and conjugated systems that can tautomerize.\n6. Generate all tautomeric forms computationally (e.g., using ChemAxon’s tautomer enumeration).\n7. Filter tautomer set by chemical stability and likely physiological pH state.\n8. Catalog each unique stereoisomer–tautomer combination for downstream analysis.\n\n[TOO_HARD]\nPlease provide the detailed molecular structure (SMILES or high-resolution 2D/3D diagram) of Xantheraquin so we can enumerate and classify its specific chiral centers and tautomeric forms.\nCoT-SC agent 0XNI, evaluating physicochemical properties, thinking: Sub-task 2 requires concrete structural representations (e.g., SMILES or 3D coordinates) for each stereoisomeric and tautomeric form of Xantheraquin to compute accurate physicochemical descriptors. Without those details, we can only outline a general protocol. The question is too open-ended for precise values, so I will provide the evaluation workflow and then request the missing structural data.; answer: General workflow to evaluate physicochemical properties of each chiral/tautomeric form:\n1. Protonation/tautomeric state analysis: predict dominant species at physiological pH (pKa calculations using quantum methods or tools like Marvin).\n2. Lipophilicity and solubility: compute logP/logD (e.g., with ALOGPS or ChemAxon), aqueous solubility predictions.\n3. Conformational energy: perform geometry optimizations (DFT or force field) to estimate relative stability of each stereoisomer and tautomer.\n4. Dipole moment and polar surface area: calculate via quantum chemical methods to infer membrane permeability and hydrogen-bonding potential.\n5. Strain and torsional energies: analyze low-energy conformers to assess the likelihood of bioactive conformations.\n6. Druglikeness filters: check Lipinski’s rule of five, Veber criteria, and other ADME-related descriptors for each form.\n7. Rank the forms by a composite score balancing stability and predicted bioavailability; prioritize forms that are neutral or singly charged, moderately lipophilic (logD ~1–3), and low in strain.\n\n[TOO_HARD]\nPlease provide the SMILES or high-resolution 3D structures for all proposed chiral and tautomeric forms of Xantheraquin so we can compute specific physicochemical parameters and complete the evaluation.\nCoT-SC agent uoc2, evaluating physicochemical properties, thinking: To evaluate the stability and biological relevance of each stereoisomer–tautomer, one must compute their key physicochemical parameters (e.g., pKa, logP, solubility, conformational energy, tautomeric equilibrium constants) using quantum mechanics and cheminformatics tools. However, without the explicit structures or SMILES/InChI for each form, numerical evaluation isn’t possible.; answer: General approach to evaluate physicochemical properties of each form:\n1. Generate 3D geometries and perform geometry optimizations (e.g., DFT or semi-empirical QM).\n2. Calculate relative energies of tautomers to predict equilibrium distributions (e.g., Gibbs free energies).\n3. Predict pKa values for ionizable sites to assess protonation states at physiological pH.\n4. Compute lipophilicity (logP/logD) and aqueous solubility predictions.\n5. Perform conformational sampling (e.g., molecular mechanics/MD) to assess flexibility and intramolecular H-bonding.\n6. Estimate membrane permeability and PSA (polar surface area) for potential bioavailability.\n7. Rank forms by combined stability and drug-like properties for prioritization.\n[TOO_HARD]\nPlease provide the exact chemical structures or SMILES/InChI strings for each chiral and tautomeric form of Xantheraquin so that these calculations can be carried out quantitatively.\nCoT-SC agent ZTsD, evaluating physicochemical properties, thinking: Without explicit structural details (e.g., SMILES/InChI or 3D coordinates) of Xantheraquin’s stereoisomers and tautomers, we cannot compute exact physicochemical values. However, we can outline the key steps for evaluation and highlight where specific data is needed.; answer: Workflow to evaluate physicochemical properties of each chiral/tautomeric form:\n1. Generate 3D conformers for each stereoisomer–tautomer combination using tools like RDKit or OpenEye.\n2. Compute pKa values (e.g., with Marvin or Epik) to predict predominant ionization state at physiological pH.\n3. Calculate lipophilicity (logP/logD) using ALOGPS or ChemAxon.\n4. Estimate aqueous solubility and TPSA for membrane permeability prediction.\n5. Run quantum mechanical energy minimizations (e.g., DFT) to compare relative thermodynamic stabilities.\n6. Perform short molecular dynamics simulations in explicit solvent to assess conformational flexibility and solvation energies.\n7. Rank forms by a composite score combining stability, solubility, and predicted permeability.\n8. Prioritize forms with favorable stability and drug-like physicochemical profiles for further in vitro validation.\n[TOO_HARD]\nPlease provide the detailed molecular structures of each chiral and tautomeric form (e.g., SMILES or 3D files) so we can calculate their specific physicochemical properties and rank them accurately.\nReflexion CoT agent aQfl, prioritizing forms, thinking: Sub-task 3 requires ranking specific stereoisomeric and tautomeric forms by their precise physicochemical parameters (e.g., logD, pKa, conformational energies). Without concrete structural representations (e.g., SMILES or 3D coordinates), we can only outline a general prioritization framework but cannot assign actual identities or values. Therefore, additional structural information is needed to finalize the list.; answer: General prioritization framework for Xantheraquin’s isomeric forms:\n1. Neutral keto tautomers predominant at pH 7.4 with logD between 1–3, low conformational strain, and favorable polar surface area.\n2. Singly protonated (enol or zwitterionic) forms with moderate lipophilicity (logD ~0–2) and pKa values near physiological pH enhancing binding potential.\n3. Minor high-energy tautomers or doubly charged species with poor membrane permeability and high strain—deprioritize for initial docking.\n4. Among stereoisomers, prioritize those with lowest calculated DFT/force-field energies and R/S configurations predicted to match the chiral environment of the target’s binding pocket.\n\n[TOO_HARD]\nPlease provide the SMILES or high‐resolution 2D/3D structures for each proposed chiral and tautomeric form of Xantheraquin so we can compute accurate energetics, pKa, and logD values to refine this prioritization.\nCritic agent RqcZ, providing feedback, thinking: The proposed prioritization framework is conceptually sound but hampered by a lack of concrete structural data. Without SMILES or 3D coordinates for each tautomeric and stereoisomeric form, the values for logD, pKa, and conformational energies remain speculative. Additionally, the framework omits considerations of tautomer interconversion kinetics, actual population distributions under physiological conditions, and explicit stereochemical matching to the binding site’s chiral environment. As a result, the prioritization cannot be definitively applied or validated.; answer: Prioritization protocol:\n1. Enumerate all stereoisomers and tautomeric forms using canonical SMILES or 3D structures.\n2. Predict pKa values and corresponding populations at pH 7.4, then calculate logD for each form.\n3. Optimize conformers via DFT or high-quality force fields to estimate relative conformational energies.\n4. Rank forms by (a) estimated population fraction >5%, (b) energy within ~5 kcal/mol of the lowest-energy structure, and (c) logD between 1–3 for optimal permeability.\n5. Perform preliminary induced-fit or flexible docking on the top-ranked forms to assess chiral complementarity with the binding pocket.\n[TOO_HARD]\nPlease provide SMILES or high-resolution 2D/3D structural representations for each proposed tautomeric and stereoisomeric form so we can compute accurate physicochemical properties and finalize the prioritization.\nReflexion CoT agent aQfl, refining prioritization, thinking: Without specific structural representations (e.g., SMILES or 3D coordinates) for each tautomeric and stereoisomeric form of Xantheraquin, we cannot compute exact pKa, logD, or conformational energies. We can only propose a generic prioritization framework based on typical physicochemical trends and likely bioactive species.; answer: 1. Neutral keto tautomers predominant at pH 7.4 (logD ~1–3), low conformational strain, favorable PSA—highest priority for initial docking.\n2. Singly protonated enol or zwitterionic forms with moderate lipophilicity (logD ~0–2) and pKa near physiological pH—second priority.\n3. Minor high-energy tautomers or doubly charged species with poor membrane permeability and high strain—deprioritize.\n4. Within each tautomeric group, prioritize stereoisomers with the lowest calculated DFT/force-field energies and R/S configurations predicted to complement the chiral binding pocket.\n[TOO_HARD]\nPlease provide the SMILES or high-resolution 3D structures for each chiral and tautomeric form of Xantheraquin to calculate precise energetics, pKa, and logD values and finalize the ranking.\nCoT agent drEc, assessing quantum mechanical calculations, thinking: Predicting ligand–target interactions using quantum mechanical (QM) methods can yield highly accurate binding energies and insight into electronic effects, but it is computationally prohibitive to apply QM to every tautomeric and stereoisomeric form. Without specific 3D structures, protonation states, and target details, one cannot estimate workload or accuracy. Therefore, feasibility is low for broad screening but acceptable for targeted QM/MM refinement once top candidates are identified.; answer: Quantum mechanical calculations on the single most stable chiral form can provide detailed insight into electronic interactions and binding energetics, but they are too resource-intensive to apply across all tautomeric and stereoisomeric forms at once. Instead, use docking and MD to filter candidates, then apply QM/MM for lead refinement.  \n[TOO_HARD]  \nPlease supply high-resolution 3D coordinates of the protein binding site and the predicted dominant tautomeric and protonation states of Xantheraquin, or decompose the workflow into: (1) docking-based screening, (2) MD-based stability assessment, (3) targeted QM/MM refinement.\nDebate agent qeIb, round 0, debating integration of in silico and in vitro, thinking: Integrating computational predictions with experimental binding assays is critical to validate docking hypotheses and avoid wasted resources on false positives. Practical considerations include selection of appropriate biophysical assays (e.g., SPR, ITC), ensuring compound purity and correct stereochemistry/tautomeric form, defining assay conditions that mimic physiological pH and ionic strength, and correlating measured Kd values with in silico scores to refine models. Without details on the protein construct, compound availability, and predicted dominant tautomeric/protonation states, protocol design remains speculative.; answer: Combine in silico predictions with preliminary in vitro binding affinity assays to validate the most promising forms before extensive docking studies. Implement an iterative workflow: 1) Use computational docking to rank the top 3–5 tautomeric and chiral forms; 2) Synthesize or isolate each pure form and confirm its structure (e.g., by NMR/MS); 3) Perform biophysical binding assays (SPR or ITC) under physiologically relevant buffer conditions to measure Kd and binding thermodynamics; 4) Correlate experimental affinities with docking scores to identify and prioritize the biologically active form; 5) Refine docking protocols (adjust protonation states, solvation models) based on assay feedback and proceed with large-scale in silico screening. [TOO_HARD]\nPlease provide the high-resolution protein binding-site structure, the predicted dominant tautomeric and protonation states of Xantheraquin, and the availability (quantity/purity) of each stereoisomeric form to finalize assay design and conditions.\nDebate agent WIoB, round 0, debating integration of in silico and in vitro, thinking: To validate in silico predictions before embarking on large‐scale docking, you must marry computational triage with targeted experimental assays. This requires narrowing the candidate set, ensuring material availability, choosing robust binding assays, and building feedback loops to refine the computational models based on real data.; answer: Proposed workflow:\n1) In silico triage: dock all protonation/tautomeric and stereoisomeric forms of Xantheraquin against the bacterial target and rank by predicted binding energy, key interactions, and physicochemical feasibility.\n2) Candidate selection: pick the top 3–5 ranked forms considering synthetic accessibility, solubility, and stability.\n3) Biophysical assays: express and purify the target binding domain; test each selected form in parallel using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) to measure Kd, kinetics, and thermodynamic parameters. Include controls for nonspecific binding and aggregation.\n4) Data integration: compare experimental affinities with docking scores, identify systematic biases (e.g., overestimation of certain tautomers), and retrain scoring parameters or adjust protonation states.\n5) Iteration: rescreen refined set of forms with updated docking parameters and repeat minimal in vitro validation to converge on the most biologically relevant tautomeric/stereoisomeric species.\n\nPractical considerations: assay throughput vs. cost (SPR allows 96-well plate format for medium throughput), compound solubility limits, protein stability, and the need for sufficient compound quantities. This integrated approach reduces false positives and directs extensive docking to experimentally vetted forms.\nFinal Decision agent, deciding on integration, thinking: Integrating in silico docking with preliminary in vitro binding assays is critical to validate which tautomeric and chiral forms of Xantheraquin actually bind the target, reducing false positives and guiding efficient resource use. However, key details—such as the high-resolution protein binding-site structure, predicted dominant tautomers/protonation states, and availability of pure stereoisomers—are missing, making precise assay design speculative.; answer: Combine in silico predictions with preliminary in vitro binding affinity assays to validate the most promising forms before extensive docking studies. Proposed workflow:\n1) Perform initial docking of all relevant tautomeric and chiral forms; rank the top 3–5 candidates by predicted binding energy and key interactions.\n2) Obtain or synthesize each pure form; confirm identity and purity (e.g., NMR, MS).\n3) Conduct biophysical binding assays (SPR or ITC) under physiologically relevant conditions to measure Kd, kinetics, and thermodynamics.\n4) Correlate experimental affinities with docking scores, identify systematic deviations, and refine computational models (protonation states, solvation models).\n5) Iterate: rescreen refined set and perform minimal in vitro validation to converge on the biologically active species.\n[TOO_HARD]\nPlease provide the high-resolution structure of the bacterial target’s binding site, the predicted dominant tautomeric and protonation states of Xantheraquin under assay conditions, and the quantity/purity available for each stereoisomeric form.\nCoT agent ZwbN, evaluating pharmacokinetics and ADME, thinking: Focusing on pharmacokinetics and ADME via molecular dynamics early can help predict solvation, membrane permeability, metabolite formation, and compound stability—refining lead selection beyond static binding poses. However, reliable MD requires accurate definitions of all tautomeric, protonation, and stereochemical states to parameterize force fields and simulate realistic physiological environments. Without this, any PK/ADME predictions will be undermined by structural uncertainties.; answer: Integrating MD‐based ADME and PK assessments at the initial docking stage allows you to:\n1. Model dynamic ligand–solvent and ligand–membrane interactions to predict permeability and distribution.\n2. Identify potential metabolic “hot spots” via conformational sampling and water networks around labile bonds.\n3. Refine compound selection by coupling binding stability with predicted bioavailability and clearance profiles.\n\nHowever, given Xantheraquin’s multiple chiral centers and tautomers, MD simulations will be unreliable without precise structures.  [TOO_HARD]\nPlease provide high‐resolution 3D coordinates or SMILES strings for each tautomeric and stereoisomeric form (including protonation states) so that accurate force‐field parameters, pKa, and logP calculations can be performed prior to ADME/PK simulations.", iteration_idx=1)]